Simeon J. George, M.D., M.B.A. has served on our Board of Directors since April 2015. He is the Chief Executive Officer and Managing Partner of SR One Capital Management, LP, a transatlantic biotech venture capital firm, a role he has held since September 2020. Prior to leading SR One as an independent firm, Dr. George served as Chief Executive Officer and President of S.R. One, Limited (now GSK Equity Investments, Limited), an indirect, wholly owned subsidiary of GlaxoSmithKline plc, where he had been employed since 2007.
Dr. George co-founded Nkarta, Inc. (NKTX), a clinical-stage biopharmaceutical company, and currently serves on its board of directors—a position he has held since February 2020 (and previously from July 2015 to September 2017). He also serves on the board of Design Therapeutics, Inc. (DSGN), another clinical-stage biopharmaceutical company. Previously, Dr. George has served on the boards of Principia Biopharma Inc., Progyny, Inc. (PGNY), and Turning Point Therapeutics, Inc., among others.
Earlier in his career, Dr. George worked as a consultant at Bain & Company and in investment banking at Goldman Sachs. He earned his M.D. from the University of Pennsylvania School of Medicine and his M.B.A. from the Wharton School of the University of Pennsylvania. He also holds a B.A. in Neuroscience from Johns Hopkins University.
What is Simeon George's net worth?
The estimated net worth of Simeon George is at least $792.64 thousand as of October 14th, 2026. Dr. George owns 15,486 shares of CRISPR Therapeutics stock worth more than $792,635 as of November 4th. This net worth evaluation does not reflect any other investments that Dr. George may own. Learn More about Simeon George's net worth.
How do I contact Simeon George?
Has Simeon George been buying or selling shares of CRISPR Therapeutics?
During the last ninety days, Simeon George has sold $720,329.82 in shares of CRISPR Therapeutics stock. Most recently, Simeon George sold 14,514 shares of the business's stock in a transaction on Wednesday, October 14th. The shares were sold at an average price of $49.63, for a transaction totalling $720,329.82. Following the completion of the sale, the director now directly owns 15,486 shares of the company's stock, valued at $768,570.18. Learn More on Simeon George's trading history.
Who are CRISPR Therapeutics' active insiders?
CRISPR Therapeutics' insider roster includes Ali Behbahani (Director), Bradley Bolzon (Director), Julianne Bruno (COO), Kurt Emster (Director), Simeon George (Director), John Greene (Director), Tony Ho (VP), James Kasinger (General Counsel), Lawrence Klein (COO), Samarth Kulkarni (CEO), Rodger Novak (President), Naimish Patel (Chief Medical Officer), Raju Prasad (CFO), and Michael Tomsicek (CFO). Learn More on CRISPR Therapeutics' active insiders.
Are insiders buying or selling shares of CRISPR Therapeutics?
In the last year, insiders at the sold shares 19 times. They sold a total of 239,172 shares worth more than $12,836,637.11. The most recent insider tranaction occured on October, 19th when CEO
Samarth Kulkarni sold 47,837 shares worth more than $2,381,325.86. Insiders at CRISPR Therapeutics own 5.2% of the company.
Learn More about insider trades at CRISPR Therapeutics. Information on this page was last updated on 10/19/2026.
